Overview

Meta-Iodobenzylguanidine (123I-mIBG) Scintigraphy Imaging in Patients With Heart Failure and Control Subjects Without Cardiovascular Disease

Status:
Completed

Trial end date:
2008-09-01

Target enrollment:

Participant gender:

Summary

The study is designed to study the utility of 123I-mIBG as a diagnostic imaging agent to predict cardiac outcome in subjects with heart failure and in comparison to subjects without cardiovascular disease.

Phase:

Phase 3

Details

Lead Sponsor:

GE Healthcare

Treatments:

3-Iodobenzylguanidine